Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.5%

1 terminated/withdrawn out of 65 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

9%

6 trials in Phase 3/4

Results Transparency

0%

0 of 12 completed trials have results

Key Signals

18 recruiting

Enrollment Performance

Analytics

Phase 2
19(44.2%)
N/A
15(34.9%)
Phase 3
4(9.3%)
Phase 1
3(7.0%)
Phase 4
2(4.7%)
43Total
Phase 2(19)
N/A(15)
Phase 3(4)
Phase 1(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (65)

Showing 20 of 65 trials
NCT07541001Phase 2Active Not Recruiting

PRL3-Zumab in Patients With Advanced Solid Tumors

Role: collaborator

NCT07209787Phase 4Recruiting

SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

Role: collaborator

NCT07405346Not ApplicableEnrolling By Invitation

A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy

Role: collaborator

NCT07263347Not Yet Recruiting

DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes

Role: lead

NCT07264998Not Yet Recruiting

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

Role: lead

NCT07264985Not Yet Recruiting

Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib

Role: lead

NCT07250204Not Yet Recruiting

A Study on Combined Low-pass Whole-genome and Methylome Testing of Bloody Nipple Discharge Specimens for Benign-Malignant Differentiation.

Role: lead

NCT07188857Not Yet Recruiting

Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy

Role: lead

NCT02605265Phase 3Completed

Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1

Role: collaborator

NCT06280313Recruiting

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

Role: collaborator

NCT06402435Phase 2Recruiting

SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer

Role: lead

NCT07011329Active Not Recruiting

Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.

Role: lead

NCT05044871Phase 2Completed

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Role: collaborator

NCT07002346Phase 3Not Yet Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: collaborator

NCT06258863Enrolling By Invitation

Investigating the Effects of Different Incision Types on Aesthetic Outcomes and Incision-related Complications After Breast Reconstruction Surgery

Role: lead

NCT05992870Not ApplicableRecruiting

Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction

Role: lead

NCT06854107Completed

Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma

Role: collaborator

NCT06818955Phase 2Not Yet Recruiting

Orlistat Overcoming Third-generation EGFR-TKI Resistance

Role: collaborator

NCT05021328Phase 1Completed

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

Role: lead

NCT05431621Completed

Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers

Role: collaborator